NewsRoom Articles - Page 1396 of 1437

TuesdayDec 06, 2016 1:30 pm

U.S. Geothermal (HTM) Starts Presentation at LD Micro Main Event

U.S. Geothermal (NYSE: HTM) is a renewable energy company focused on the development, production and sale of electricity from geothermal energy. The company is currently operating geothermal power projects at: Neal Hot Springs, Oregon; San Emidio, Nevada; and Raft River, Idaho for a total power generation of approximately 45 MWs. It is also developing an additional 90 MWs of projects at: the Geysers, California; a second phase project at San Emidio, Nevada; Crescent Valley, Nevada; and the El Ceibillo project located near Guatemala City, Guatemala. For more information, visit the company's website at www.usgeothermal.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news…

TuesdayDec 06, 2016 1:30 pm

Ironclad Performance Wear (ICPW) Starts Presentation at LD Micro Main Event

Ironclad Performance Wear (OTC: ICPW) is a tech company that designs and manufactures work wear for various construction, do-it-yourself, industrial, sporting goods, and general services markets. The company's technical gloves are designed for individual user groups, such as carpenters, machinists, package handlers, plumbers, welders, roofers, oil and gas workers, mechanics, hunters, gardeners, and do-it-yourself users; long and short sleeved shirts; and performance jackets, pants, shorts, reflective and polo shirts, underwear, and tights. The company sells its products under the Ironclad brand through hardware stores, lumber yards, big box home centers, industrial distributors, and automotive and sporting goods retailers. For more…

TuesdayDec 06, 2016 1:30 pm

Relmada Therapeutics (RLMD) Starts Presentation at LD Micro Main Event

Relmada Therapeutics (OTC: RLMD) is a clinical-stage biotech developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated…

TuesdayDec 06, 2016 1:30 pm

Xtant Medical Holdings, Inc. (XTNT) Starts Presentation at LD Micro Main Event

Xtant Medical (NYSE: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The company's products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For more information, visit the company's…

TuesdayDec 06, 2016 1:00 pm

PCM (PCMI) Starts Presentation at LD Micro Main Event

PCM (NASDAQ: PCMI) is a multi-vendor provider of technology products and solutions, and consumer products. The company primarily sells device products, servers, storage products, networks, printers and related accessories and devices. It also provides value-added services, such as custom configured systems, software licensing asset management, image management, product asset tagging, and asset disposal services, as well as software value-added reseller services, managed services, cloud-based services, consulting, and IT management and related services. For more information, visit the company's website at www.pcm.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social…

TuesdayDec 06, 2016 1:00 pm

Ener-Core (ENCR) Starts Presentation at LD Micro Main Event

Ener-Core (OTC: ENCR) designs, develops and manufactures products that are based on power oxidizer technologies. The company's proprietary technology provides an alternative to traditional methods of destroying gaseous pollution by enabling industrial facilities to generate on-site power from their waste gases. Its products include Ener-Core PowerStation EC250 and Ener-Core Powerstation KG2-3G/GO, which have applications in landfills, distilleries, and wastewater treatment plants, as well as various industrial processes. For more information, visit the company's website at www.ener-core.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted…

TuesdayDec 06, 2016 1:00 pm

Fusion Telecommunications (FSNN) Starts Presentation at LD Micro Main Event

Fusion Telecommunications (NASDAQ: FSNN) provides integrated cloud solutions to small, medium and large businesses. The company's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud communications, cloud connectivity, and cloud computing. Fusion's innovative, yet proven cloud solutions are designed to lower the cost of ownership, and deliver new levels of security, flexibility, scalability, and speed of deployment. For more information, visit the company's website at www.fusionconnect.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news…

TuesdayDec 06, 2016 1:00 pm

IntelliPharmaCeutics International (IPCI) Starts Presentation at LD Micro Main Event

IntelliPharmaCeutics International (NASDAQ: IPCI) is a pharmaceutical company that engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. For more information, visit the company's website at www.intellipharmaceutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…

TuesdayDec 06, 2016 12:37 pm

Cellceutix Corp. (CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, Piques Peer Interest along the Way

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal indications – also set the company on course to achieve another season of remarkable progress. Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s…

TuesdayDec 06, 2016 12:30 pm

Citius Pharmaceuticals (CTXR) Starts Presentation at LD Micro Main Event

Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products. The company has a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. By using previously approved drugs with substantial safety and efficacy data, the company seeks to reduce the risks associated with pharmaceutical product development and regulatory requirements, and focuses on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, visit the company's website at www.citiuspharma.com. About NetworkNewsWire NetworkNewsWire (NNW)…